PT-141 10mg

PT-141 (also known as bremelanotide) is a synthetic peptide that promotes sexual wellness by acting on the central nervous system rather than the vascular system. It is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) and is frequently used off-label to enhance sexual function in men and women. 

Five attributes of PT-141 include:

• Mechanism of Action: This peptide acts on the central nervous system by targeting melanocortin receptors in the brain. This differs from other treatments that focus primarily on local vascular blood flow.
• FDA-Approved Indication: It is clinically recognized and FDA-approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in specific patient populations.
• Alternative Pathway: Because it utilizes a biological pathway distinct from phosphodiesterase type 5 (PDE5) inhibitors, it may be considered for individuals where traditional therapies are not clinically indicated.
• Administration Profile: The medication is designed for as-needed administration rather than a continuous daily dosing schedule.
• Clinical Monitoring: As a prescription therapy, its use involves clinical oversight to monitor for potential side effects such as nausea or blood pressure changes.